Product image of Meropenem Bradex (Meropenem Anhydrous) supplied by GNH India

Meropenem Bradex

Active Ingredient:
Meropenem Anhydrous
Origin:
EU

Meropenem Bradex (Meropenem Anhydrous)

Meropenem, the active ingredient in Meropenem Bradex, is a carbapenem antibiotic presented as an intravenous solution for IV use. It treats severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, septicemia, and meningitis in hospitalized patients. It is indicated for use in adult and pediatric patients when alternative therapies are unsuitable.

GNH India supplies Meropenem Bradex as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, and pharmacies worldwide, with a focus on quality and regulatory compliance.

Manufacturer / TM Owner

Bradex S.A.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Meropenem Bradex is a carbapenem antibiotic used to treat serious bacterial infections across several organ systems.

  • Complicated intra‑abdominal infections: Provides broad‑spectrum coverage to eradicate Gram‑negative, Gram‑positive and anaerobic pathogens.
  • Complicated urinary tract infections: Eliminates resistant uropathogens causing pyelonephritis and cystitis.
  • Nosocomial pneumonia: Treats hospital‑acquired lung infections, including ventilator‑associated pneumonia.
  • Septicemia: Offers rapid bactericidal activity in bloodstream infections.
  • Meningitis: Penetrates the cerebrospinal fluid to treat bacterial meningitis caused by susceptible organisms.

How It Works

  • Meropenem binds with high affinity to penicillin‑binding proteins (PBPs) on bacterial cell walls, inhibiting the final transpeptidation step of peptidoglycan synthesis. This disruption weakens the cell wall, leading to osmotic instability and bacterial cell lysis. Its broad spectrum includes many Gram‑negative, Gram‑positive and anaerobic bacteria, and it is resistant to most β‑lactamases.

Side Effects

Adverse reactions may occur with meropenem therapy.

Common Side Effects

  • Nausea: mild to moderate upset stomach.
  • Vomiting: occasional emesis.
  • Diarrhea: may be watery or loose.
  • Rash: skin erythema or pruritus.
  • Headache: transient cephalic discomfort.
  • Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects

  • Seizures: especially in patients with renal impairment or CNS disorders.
  • Clostridioides difficile‑associated diarrhea: severe colitis risk.
  • Anaphylaxis: acute hypersensitivity reaction.
  • Renal toxicity: acute kidney injury in susceptible individuals.
  • Severe liver injury: rare hepatitis or cholestasis.

Precautions & Warnings

Use meropenem with caution and monitor patients for specific safety concerns.

  • Renal impairment: adjust dose based on creatinine clearance.
  • Hypersensitivity: discontinue if signs of allergic reaction appear.
  • Pregnancy: safety not established; weigh benefits against potential risks.
  • Seizure risk: monitor neurologic status, especially in patients with CNS disorders.
  • Liver function: check hepatic enzymes periodically.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Meropenem may interact with other medicines; some combinations require avoidance while others need monitoring.

Major Interactions (Avoid)

  • Valproic acid: carbapenems reduce serum valproate levels, increasing seizure risk.
  • Other carbapenems: concurrent use offers no added benefit and may increase toxicity.

Moderate Interactions (Monitor Closely)

  • Diuretics: may enhance nephrotoxic potential.
  • Aminoglycosides: monitor renal function when combined.
  • Warfarin: observe INR for possible anticoagulation changes.
  • Oral contraceptives: efficacy may be reduced; consider alternative contraception.

Frequently Asked Questions

Meropenem Bradex is indicated for severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired (nosocomial) pneumonia, septicemia, and bacterial meningitis when other antibiotics are unsuitable.

Meropenem inhibits bacterial cell wall synthesis by binding to penicillin‑binding proteins, preventing the cross‑linking of peptidoglycan strands. This leads to weakened cell walls, osmotic instability and ultimately bacterial cell death.

The dose of Meropenem Bradex is determined by the prescribing clinician based on the type and severity of infection, patient weight, renal function and local guidelines. No fixed regimen is provided here.

Safety data for Meropenem in pregnancy and lactation are limited. The product is classified as pregnancy category unknown, so clinicians must weigh potential benefits against possible risks before prescribing to pregnant or nursing women.

To order, submit an enquiry on the Meropenem Bradex product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Meropenem shares the broad‑spectrum activity of the carbapenem class but offers a slightly wider coverage against Pseudomonas aeruginosa and some resistant Gram‑negative organisms compared with imipenem. Choice among carbapenems depends on local resistance patterns, patient factors and pharmacokinetic considerations.

Meropenem Bradex should be stored at 2‑8 °C, kept refrigerated, protected from light, and must not be frozen or shaken. Once reconstituted, it should be used within the time frame specified in the product labeling.

Meropenem Bradex is supplied for intravenous infusion. It is administered by a healthcare professional through a sterile IV line, typically over 15‑30 minutes, following the dose and infusion rate prescribed by the treating physician.

The most serious adverse events include seizures (especially in patients with renal dysfunction or CNS disorders), severe allergic reactions such as anaphylaxis, Clostridioides difficile‑associated colitis, and rare cases of acute kidney or liver injury.

Patients with a known hypersensitivity to meropenem, other carbapenems, or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal impairment, a history of seizures, or those taking valproic acid.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Meropenem Anhydrous

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT